Synergistic Effect Between Cisplatin and Sunitinib Malate on Human Urinary Bladder-cancer Cell Lines

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2013 Dec 27

PMID 24369536

Citations 8

Authors

Regina Arantes-Rodrigues

Rosario Pinto-Leite

Lio Fidalgo-Goncalves

Carlos Palmeira

Lucio Santos

Aura Colaco

Paula Oliveira

Affiliations

Soon will be listed here.

Abstract

The aim of this paper is to analyse sunitinib malate in vitro ability to enhance cisplatin cytotoxicity in T24, 5637, and HT1376 human urinary bladder-cancer cell lines. Cells were treated with cisplatin (3, 6, 13, and 18 μM) and sunitinib malate (1, 2, 4, 6, and 20 μM), either in isolation or combined, over the course of 72 hours. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay, acridine orange, and monodansylcadaverine staining and flow cytometry were performed. The combination index (CI) was calculated based on the Chou and Talalay method. In isolation, cisplatin and sunitinib malate statistically (P < 0.05) decrease cell viability in all cell lines in a dose-dependent manner, with the presence of autophagic vacuoles. A cell cycle arrest in early S-phase and in G0/G1-phase was also found after exposure to cisplatin and sunitinib malate, in isolation, respectively. Treatment of urinary bladder-cancer cells with a combination of cisplatin and sunitinib malate showed a synergistic effect (CI < 1). Autophagy and apoptosis studies showed a greater incidence when the combined treatment was put into use. This hints at the possibility of a new combined therapeutic approach. If confirmed in vivo, this conjugation may provide a means of new perspectives in muscle-invasive urinary bladder cancer treatment.

Citing Articles

Tannic Acid Impedes the Proliferation of Bladder Cancer Cells by Elevating Mitochondrial Pathways of Apoptosis.

Li C, Tsai B, Annseles Rajula S, Hsu C, Chen M, Kuo C Cell Biochem Biophys. 2024; 82(2):1325-1333.

PMID: 38809348 DOI: 10.1007/s12013-024-01286-w.

Sulforaphane and bladder cancer: a potential novel antitumor compound.

Zuo M, Chen H, Liao Y, He P, Xu T, Tang J Front Pharmacol. 2023; 14:1254236.

PMID: 37781700 PMC: 10540234. DOI: 10.3389/fphar.2023.1254236.

Role of Sam68 in Sunitinib induced renal cell carcinoma apoptosis.

Wu Z, Peng Y, Xiong L, Wang J, Li Z, Ning K Cancer Med. 2022; 11(19):3674-3686.

PMID: 35476809 PMC: 9554455. DOI: 10.1002/cam4.4743.

Chrysin induces cell growth arrest, apoptosis, and ER stress and inhibits the activation of STAT3 through the generation of ROS in bladder cancer cells.

Xu Y, Tong Y, Ying J, Lei Z, Wan L, Zhu X Oncol Lett. 2018; 15(6):9117-9125.

PMID: 29805643 PMC: 5958737. DOI: 10.3892/ol.2018.8522.

Anticancer effect of S-allyl-L-cysteine via induction of apoptosis in human bladder cancer cells.

Ho J, Kang M, Lee S, Oh J, Hong S, Lee S Oncol Lett. 2017; 15(1):623-629.

PMID: 29285203 PMC: 5738700. DOI: 10.3892/ol.2017.7280.

References

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

Gallagher D, Milowsky M, Gerst S, Ishill N, Riches J, Regazzi A . Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol. 2010; 28(8):1373-9. DOI: 10.1200/JCO.2009.25.3922. View

Abrams T, Lee L, Murray L, Pryer N, Cherrington J . SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003; 2(5):471-8. View

Liang J, Shao S, Xu Z, Hennessy B, Ding Z, Larrea M . The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol. 2007; 9(2):218-24. DOI: 10.1038/ncb1537. View

Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Colaco B, Lopes C, Colaco A . Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer. Biomed Pharmacother. 2013; 67(2):116-21. DOI: 10.1016/j.biopha.2012.11.007. View

Vasconcelos-Nobrega C, Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso M . In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol. 2011; 31(7):1212-21. DOI: 10.1016/j.urolonc.2011.11.002. View

Vishnu P, Colon-Otero G, Kennedy G, Marlow L, Kennedy W, Wu K . RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer. Gynecol Oncol. 2011; 124(3):589-97. PMC: 3468155. DOI: 10.1016/j.ygyno.2011.11.019. View

Konstantakou E, Voutsinas G, Karkoulis P, Aravantinos G, Margaritis L, Stravopodis D . Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol. 2009; 35(2):401-16. View

Sonpavde G, Jian W, Liu H, Wu M, Shen S, Lerner S . Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol. 2008; 27(4):391-9. DOI: 10.1016/j.urolonc.2008.03.017. View

10.

Zhao Y, Xue T, Yang X, Zhu H, Ding X, Lou L . Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells. Toxicol Appl Pharmacol. 2010; 248(1):20-7. DOI: 10.1016/j.taap.2010.07.007. View

11.

Edeline J, Loriot Y, Culine S, Massard C, Albiges L, Blesius A . Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen. Eur J Cancer. 2012; 48(8):1141-6. DOI: 10.1016/j.ejca.2012.01.022. View

12.

Mossberg A, Wullt B, Gustafsson L, Mansson W, Ljunggren E, Svanborg C . Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int J Cancer. 2007; 121(6):1352-9. DOI: 10.1002/ijc.22810. View

13.

Shu-Yin Chan E, Patel A, Hansel D, Larchian W, Heston W . Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. Urology. 2012; 80(3):736.e1-5. DOI: 10.1016/j.urology.2012.04.038. View

14.

Arantes-Rodrigues R, Colaco A, Pinto-Leite R, Oliveira P . In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer. Anticancer Res. 2013; 33(4):1273-96. View

15.

Nicoletti I, Migliorati G, Pagliacci M, Grignani F, Riccardi C . A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991; 139(2):271-9. DOI: 10.1016/0022-1759(91)90198-o. View

16.

Yoon C, Lee J, Kim B, Jeong S, Hong S, Byun S . Sunitinib malate synergistically potentiates anti-tumor effect of gemcitabine in human bladder cancer cells. Korean J Urol. 2011; 52(1):55-63. PMC: 3037508. DOI: 10.4111/kju.2011.52.1.55. View

17.

Askeland E, Newton M, ODonnell M, Luo Y . Bladder Cancer Immunotherapy: BCG and Beyond. Adv Urol. 2012; 2012:181987. PMC: 3388311. DOI: 10.1155/2012/181987. View

18.

Pan F, Tian J, Zhang X, Zhang Y, Pan Y . Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation. J Cancer Res Clin Oncol. 2011; 137(9):1397-408. DOI: 10.1007/s00432-011-1009-x. View

19.

Cheung G, Sahai A, Billia M, Dasgupta P, Khan M . Recent advances in the diagnosis and treatment of bladder cancer. BMC Med. 2013; 11:13. PMC: 3566975. DOI: 10.1186/1741-7015-11-13. View

20.

Powles T, Perry J, Shamash J, Liu W, Oliver T, Joel S . A comparison of the platinum analogues in bladder cancer cell lines. Urol Int. 2007; 79(1):67-72. DOI: 10.1159/000102917. View